Challenge of the cure: Examining the P&MA challenges of disruptive therapies in Europe
To help understand the pricing and access challenges facing disruptive therapies such as gene and cell therapy (GCT), we recently enlisted the help of payers...
Andras Ruppert is a vice president in the Life Sciences Practice at CRA. He has more than 20 years of experience working in the pharmaceutical, biotech, and medical device industries globally, solving strategic issues.
Mr. Ruppert is an expert in European healthcare systems, including their funding, evaluation, and reimbursement processes. He also helps life sciences companies to adjust internal structures and processes to the changing environment.
Prior to his role at CRA, Mr. Ruppert held senior positions at QuintilesIMS, now doing business as IQVIA, most recently as a vice president and head of their global consulting business out of Europe. He is fluent in English, German, and Norwegian.